Change in Patient-Reported Outcomes in severe eosinophilic asthma patients treated with benralizumab under real-life conditions

Trial Identifier: D3250R00053
Sponsor: AstraZeneca
NCTID:: NCT04184284
Start Date: November 2019
Primary Completion Date: December 2023
Study Completion Date: December 2023
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Germany Aschaffenburg, Germany
Germany Augsburg, Germany
Germany Bamberg, Germany
Germany Beelitz, Germany
Germany Biberach, Germany
Germany Bonn, Germany
Germany Bremen, Germany
Germany Cottbus, Germany
Germany Darmstadt, Germany
Germany Dresden, Germany
Germany Duesseldorf, Germany
Germany Dusseldorf, Germany
Germany Flensburg, Germany
Germany Frankfurt, Germany
Germany Fuerstenwalde, Germany
Germany Furstenwalde, Germany
Germany Gelsenkirchen, Germany
Germany Gerlingen, Germany
Germany Gotingen, Germany
Germany Halberstadt, Germany
Germany Halle, Germany
Germany Hamburg, Germany
Germany Hannover, Germany
Germany Heidelberg, Germany
Germany Hemer, Germany
Germany Hettstedt, Germany
Germany Ibbenbueren, Germany
Germany Immenhausen, Germany
Germany Konstanz, Germany
Germany Leipzig, Germany
Germany Magdeburg, Germany
Germany Marburg, Germany
Germany Markkleeberg, Germany
Germany Munchen, Germany
Germany Neu-Isenburg, Germany
Germany Peine, Germany
Germany Radebeul, Germany
Germany Regensburg, Germany
Germany Reinfeld, Germany
Germany Rheine, Germany
Germany Rostock, Germany
Germany Roth, Germany
Germany Saalfeld, Germany
Germany Schleswig, Germany
Germany Teuchern, Germany
Germany Treuenbrietzen, Germany
Germany Waren, Germany
Germany Warendorf, Germany
Germany Wedel, Germany
Germany Witten, Germany